Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company is headquartered in San Diego, California and currently employs 144 full-time employees. The company went IPO on 2019-02-08. Seralutinib, also known as GB002, is an investigational inhaled, small-molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. Seralutinib is designed to target the mechanisms that underlie pulmonary hypertension and to be delivered to the site of disease, via dry powder inhaler. Seralutinib is being evaluated in a Phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH). Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways.
Follow-Up Questions
Gossamer Bio Inc의 CEO는 누구입니까?
Mr. Faheem Hasnain은 2018부터 회사에 합류한 Gossamer Bio Inc의 Chairman of the Board입니다.
GOSS 주식의 가격 성능은 어떻습니까?
GOSS의 현재 가격은 $2.25이며, 전 거래일에 increased 2.87% 하였습니다.
Gossamer Bio Inc의 주요 사업 주제나 업종은 무엇입니까?
Gossamer Bio Inc은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
Gossamer Bio Inc의 시가총액은 얼마입니까?
Gossamer Bio Inc의 현재 시가총액은 $517.9M입니다
Gossamer Bio Inc는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 9명의 분석가가 Gossamer Bio Inc에 대한 분석 평가를 실시했으며, 이는 5명의 강력한 매수, 7명의 매수, 3명의 보유, 0명의 매도, 그리고 5명의 강력한 매도를 포함합니다
